CDEK
← All drugs Report issue

firibastat

Small moleculeexperimental

Clinical trial activity

11 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
7
Phase 3
3
Phase 4
0

Earliest trial started Jul 1, 2010 (NCT00947661)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

N[C@@H](CCS(=O)(=O)O)CSSC[C@@H](N)CCS(=O)(=O)O
Mol. weight
368.52 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • qgc001
  • sparc0912

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04857840Phase 3Aug 5, 2021Pharmaceutical Research Associates, Inc. (PRA), Quantum Genomics SA, University of Chicago
NCT04277884Phase 3Mar 1, 2020Quantum Genomics SA
NCT04792333Phase 1Sep 17, 2019Eurofins, Quantum Genomics SA
NCT03715998Phase 2Jun 4, 2019Quantum Genomics SA, Sorbonne University
NCT03714685Phase 1Feb 15, 2019Quantum Genomics SA, Quotient
NCT03198793Phase 2Oct 13, 2017Quantum Genomics SA, Tulane University
NCT02780180Phase 2Jun 1, 2016Quantum Genomics SA, University of Lorraine
NCT02322450Phase 2Jan 1, 2015Quantum Genomics SA
NCT01900184Phase 1Dec 1, 2012Quantum Genomics SA
NCT01900171Phase 1Feb 1, 2012Quantum Genomics SA
NCT00947661Phase 3Jul 1, 2010SPARC
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Quantum Genomics SAFor profit101032012
EurofinsFor profit1012019
Pharmaceutical Research Associates, Inc. (PRA)For profit1012021
QuotientFor profit1012019
Sorbonne UniversityAcademic/Hospital1012019
SPARCFor profit1112010
Tulane UniversityAcademic/Hospital1012017
University of ChicagoAcademic/Hospital1012021
University of LorraineAcademic/Hospital1012016
9 organizations
Page 1 / 1